Skip to main content
Top
Published in: Acta Diabetologica 4/2016

01-08-2016 | Review Article

Diabetology and oncology meet in a network model: union is strength

Authors: Marco Gallo, Luigi Gentile, Emanuela Arvat, Oscar Bertetto, Gennaro Clemente

Published in: Acta Diabetologica | Issue 4/2016

Login to get access

Abstract

Diabetes and cancer are increasingly common conditions, and the management of cancer patients with diabetes is often challenging. Diabetes in cancer patients poses several complex clinical issues, including which treatment is suitable to control hyperglycemia, how to better counteract glucocorticoid-induced hyperglycemia, and how to manage nutritional problems of cachectic patients and glucose variability linked to artificial nutrition. A key aspect to consider is the patients’ position on the trajectory of the oncologic disease, both to establish which level of glycemic control should be pursued and to decide the most suitable antidiabetic treatment to recommend. Endocrinologists are rarely involved in the management of patients with advanced cancer. Furthermore, lack of guidelines results in a “trial-and-error” approach, often with suboptimal disease management. Lastly, cancer survivors represent a frequently underestimated category of patients at higher cardiometabolic risk. A practical solution for these challenges lies in the implementation of care networks based on a close partnership and ongoing communication between oncologists, endocrinologists, and nutritionists, placing the patient at the center of the care process. At the same time, universities and scientific societies should play a key role in promoting research into areas of intersection of oncology and endocrinology, in raising awareness of common possibilities of primary and secondary prevention of metabolic and oncologic diseases, as well as specific challenges of managing diabetes and cancer, and proper training of health workers, while also supporting the shared implementation of effective management strategies.
Appendix
Available only for authorised users
Literature
1.
go back to reference Greenwood M, Wood F (1914) The relation between the cancer and diabetes death-rates. J Hyg (Lond) 14:83–118CrossRef Greenwood M, Wood F (1914) The relation between the cancer and diabetes death-rates. J Hyg (Lond) 14:83–118CrossRef
2.
go back to reference Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMedPubMedCentral Hemkens LG, Grouven U, Bender R et al (2009) Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 52:1732–1744CrossRefPubMedPubMedCentral
4.
go back to reference Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103–1123CrossRefPubMed Vigneri P, Frasca F, Sciacca L, Pandini G, Vigneri R (2009) Diabetes and cancer. Endocr Relat Cancer 16:1103–1123CrossRefPubMed
5.
go back to reference Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764CrossRefPubMedPubMedCentral Barone BB, Yeh HC, Snyder CF et al (2008) Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA 300:2754–2764CrossRefPubMedPubMedCentral
7.
go back to reference Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083CrossRefPubMedPubMedCentral Huxley R, Ansary-Moghaddam A, Berrington de Gonzalez A, Barzi F, Woodward M (2005) Type-II diabetes and pancreatic cancer: a meta-analysis of 36 studies. Br J Cancer 92:2076–2083CrossRefPubMedPubMedCentral
8.
go back to reference Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687CrossRefPubMed Larsson SC, Orsini N, Wolk A (2005) Diabetes mellitus and risk of colorectal cancer: a meta-analysis. J Natl Cancer Inst 97:1679–1687CrossRefPubMed
9.
go back to reference Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226–232PubMed Heuson JC, Legros N (1972) Influence of insulin deprivation on growth of the 7,12-dimethylbenz(a)anthracene-induced mammary carcinoma in rats subjected to alloxan diabetes and food restriction. Cancer Res 32:226–232PubMed
10.
go back to reference Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91–106CrossRefPubMed Kaaks R, Lukanova A (2001) Energy balance and cancer: the role of insulin and insulin-like growth factor-I. Proc Nutr Soc 60:91–106CrossRefPubMed
12.
13.
go back to reference Ruiter R, Visser LE, van Herk-Sukel MP et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55:51–62CrossRefPubMed Ruiter R, Visser LE, van Herk-Sukel MP et al (2012) Risk of cancer in patients on insulin glargine and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 55:51–62CrossRefPubMed
14.
go back to reference Karlstad O, Starup-Linde J, Vestergaard P et al (2013) Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Saf 8:333–348CrossRefPubMed Karlstad O, Starup-Linde J, Vestergaard P et al (2013) Use of insulin and insulin analogs and risk of cancer—systematic review and meta-analysis of observational studies. Curr Drug Saf 8:333–348CrossRefPubMed
16.
go back to reference Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258CrossRefPubMed Bowker SL, Majumdar SR, Veugelers P, Johnson JA (2006) Increased cancer-related mortality for patients with type 2 diabetes who use sulfonylureas or insulin. Diabetes Care 29:254–258CrossRefPubMed
17.
go back to reference Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304CrossRefPubMedPubMedCentral Currie CJ, Poole CD, Jenkins-Jones S, Gale EA, Johnson JA, Morgan CL (2012) Mortality after incident cancer in people with and without type 2 diabetes: impact of metformin on survival. Diabetes Care 35:299–304CrossRefPubMedPubMedCentral
23.
go back to reference Gallo M (2013) Thyroid safety in patients treated with liraglutide. J Endocrinol Invest 36:140–145CrossRefPubMed Gallo M (2013) Thyroid safety in patients treated with liraglutide. J Endocrinol Invest 36:140–145CrossRefPubMed
25.
go back to reference Gerich JE, Bastien A (2011) Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol 4:669–683CrossRefPubMed Gerich JE, Bastien A (2011) Development of the sodium-glucose co-transporter 2 inhibitor dapagliflozin for the treatment of patients with type 2 diabetes mellitus. Expert Rev Clin Pharmacol 4:669–683CrossRefPubMed
28.
go back to reference Wiseman M (2008) The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67:253–256. doi:10.1017/S002966510800712X CrossRefPubMed Wiseman M (2008) The second World Cancer Research Fund/American Institute for Cancer Research expert report. Food, nutrition, physical activity, and the prevention of cancer: a global perspective. Proc Nutr Soc 67:253–256. doi:10.​1017/​S002966510800712​X CrossRefPubMed
31.
go back to reference American Diabetes Association (2008) Nutrition recommendation and intervention for diabetes. A position statement of the American Diabetes Association. Diabetes Care 31:S61–S278CrossRef American Diabetes Association (2008) Nutrition recommendation and intervention for diabetes. A position statement of the American Diabetes Association. Diabetes Care 31:S61–S278CrossRef
32.
go back to reference August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors (2009) A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 33:472–500CrossRefPubMed August DA, Huhmann MB, American Society for Parenteral and Enteral Nutrition (A.S.P.E.N.) Board of Directors (2009) A.S.P.E.N. clinical guidelines: nutrition support therapy during adult anticancer treatment and in hematopoietic cell transplantation. JPEN J Parenter Enteral Nutr 33:472–500CrossRefPubMed
33.
go back to reference Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia. J Diabetes 6:9–20CrossRefPubMed Perez A, Jansen-Chaparro S, Saigi I, Bernal-Lopez MR, Miñambres I, Gomez-Huelgas R (2014) Glucocorticoid-induced hyperglycemia. J Diabetes 6:9–20CrossRefPubMed
34.
35.
go back to reference Gulliford MC (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29:2728–2729CrossRefPubMed Gulliford MC (2006) Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care 29:2728–2729CrossRefPubMed
37.
go back to reference Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA (2006) Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 12:358–362CrossRefPubMed Donihi AC, Raval D, Saul M, Korytkowski MT, DeVita MA (2006) Prevalence and predictors of corticosteroid-related hyperglycemia in hospitalized patients. Endocr Pract 12:358–362CrossRefPubMed
38.
go back to reference Uzu T, Harada T, Sakaguchi M et al (2007) Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105:c54–c57CrossRefPubMed Uzu T, Harada T, Sakaguchi M et al (2007) Glucocorticoid-induced diabetes mellitus: prevalence and risk factors in primary renal diseases. Nephron Clin Pract 105:c54–c57CrossRefPubMed
39.
go back to reference Genolet P, Petite C, Petignat PA (2012) Diabète cortico-induit, une entité fréquente sans prise en charge standardisée. Rev Med Suisse 8(800–802):804–805 Genolet P, Petite C, Petignat PA (2012) Diabète cortico-induit, une entité fréquente sans prise en charge standardisée. Rev Med Suisse 8(800–802):804–805
40.
go back to reference Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M (2004) Steroid-induced diabetes in patients with neurologic diseases. Pharmacotherapy 24:508–514CrossRefPubMed Iwamoto T, Kagawa Y, Naito Y, Kuzuhara S, Kojima M (2004) Steroid-induced diabetes in patients with neurologic diseases. Pharmacotherapy 24:508–514CrossRefPubMed
41.
go back to reference Yuen KC, McDaniel PA, Riddle MC (2012) Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf) 77:224–232. doi:10.1111/j.1365-2265.2011.04242.x CrossRef Yuen KC, McDaniel PA, Riddle MC (2012) Twenty-four-hour profiles of plasma glucose, insulin, C-peptide and free fatty acid in subjects with varying degrees of glucose tolerance following short-term, medium-dose prednisone (20 mg/day) treatment: evidence for differing effects on insulin secretion and action. Clin Endocrinol (Oxf) 77:224–232. doi:10.​1111/​j.​1365-2265.​2011.​04242.​x CrossRef
42.
43.
go back to reference Fardet L, Fève B (2014) Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 74:1731–1745CrossRefPubMed Fardet L, Fève B (2014) Systemic glucocorticoid therapy: a review of its metabolic and cardiovascular adverse events. Drugs 74:1731–1745CrossRefPubMed
44.
go back to reference Umpierrez GE, Hellman R, Korytkowski MT et al (2012) Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97:16–38CrossRefPubMed Umpierrez GE, Hellman R, Korytkowski MT et al (2012) Management of hyperglycemia in hospitalized patients in non-critical care setting: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 97:16–38CrossRefPubMed
46.
go back to reference Poulson J (1997) The management of diabetes in patients with advanced cancer. J Pain Symptom Manage 13:339–346CrossRefPubMed Poulson J (1997) The management of diabetes in patients with advanced cancer. J Pain Symptom Manage 13:339–346CrossRefPubMed
47.
go back to reference Psarakis HM (2006) Clinical challenge in caring for patients with diabetes and cancer. Diabetes Spectr 19:157–162CrossRef Psarakis HM (2006) Clinical challenge in caring for patients with diabetes and cancer. Diabetes Spectr 19:157–162CrossRef
49.
go back to reference Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149. doi:10.2337/dc14-2441 CrossRefPubMed Inzucchi SE, Bergenstal RM, Buse JB et al (2015) Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 38:140–149. doi:10.​2337/​dc14-2441 CrossRefPubMed
51.
52.
go back to reference McCoubrie R, Jeffrey D, Paton C, Dawes L (2005) Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care (Engl) 14:244–248CrossRef McCoubrie R, Jeffrey D, Paton C, Dawes L (2005) Managing diabetes mellitus in patients with advanced cancer: a case note audit and guidelines. Eur J Cancer Care (Engl) 14:244–248CrossRef
53.
55.
go back to reference Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387–1392. doi:10.1093/annonc/mdn066 CrossRefPubMed Bellmunt J, Szczylik C, Feingold J, Strahs A, Berkenblit A (2008) Temsirolimus safety profile and management of toxic effects in patients with advanced renal cell carcinoma and poor prognostic features. Ann Oncol 19:1387–1392. doi:10.​1093/​annonc/​mdn066 CrossRefPubMed
60.
go back to reference Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582CrossRefPubMed Oeffinger KC, Mertens AC, Sklar CA et al (2006) Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572–1582CrossRefPubMed
61.
go back to reference Kero AE, Järvelä LS, Arola M et al (2015) Late mortality among 5-year survivors of early onset cancer: a population-based register study. Int J Cancer 136(7):1655–1664CrossRefPubMed Kero AE, Järvelä LS, Arola M et al (2015) Late mortality among 5-year survivors of early onset cancer: a population-based register study. Int J Cancer 136(7):1655–1664CrossRefPubMed
62.
go back to reference Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–1995CrossRefPubMed Lipshultz SE, Adams MJ, Colan SD et al (2013) Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association. Circulation 128:1927–1995CrossRefPubMed
63.
go back to reference Chen MH, Colan SD, Diller L (2011) Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 108:619–628CrossRefPubMed Chen MH, Colan SD, Diller L (2011) Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res 108:619–628CrossRefPubMed
64.
go back to reference Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26:1013–1032CrossRefPubMed Lancellotti P, Nkomo VT, Badano LP et al (2013) Expert consensus for multi-modality imaging evaluation of cardiovascular complications of radiotherapy in adults: a report from the European Association of Cardiovascular Imaging and the American Society of Echocardiography. J Am Soc Echocardiogr 26:1013–1032CrossRefPubMed
65.
go back to reference Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606CrossRefPubMedPubMedCentral Mulrooney DA, Yeazel MW, Kawashima T et al (2009) Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. BMJ 339:b4606CrossRefPubMedPubMedCentral
66.
go back to reference Felicetti F, D’Ascenzo F, Moretti C et al (2015) Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. Eur J Prev Cardiol 22:762–770. doi:10.1177/2047487314529348 CrossRefPubMed Felicetti F, D’Ascenzo F, Moretti C et al (2015) Prevalence of cardiovascular risk factors in long-term survivors of childhood cancer: 16 years follow up from a prospective registry. Eur J Prev Cardiol 22:762–770. doi:10.​1177/​2047487314529348​ CrossRefPubMed
67.
go back to reference De Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA (2010) The metabolic syndrome in cancer survivors. Lancet Oncol 11:193–203CrossRefPubMed De Haas EC, Oosting SF, Lefrandt JD, Wolffenbuttel BH, Sleijfer DT, Gietema JA (2010) The metabolic syndrome in cancer survivors. Lancet Oncol 11:193–203CrossRefPubMed
68.
go back to reference Green DM, Cox CL, Zhu L et al (2012) Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 30:246–255CrossRefPubMed Green DM, Cox CL, Zhu L et al (2012) Risk factors for obesity in adult survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. J Clin Oncol 30:246–255CrossRefPubMed
69.
go back to reference Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123–e136CrossRefPubMedPubMedCentral Armenian SH, Hudson MM, Mulder RL et al (2015) Recommendations for cardiomyopathy surveillance for survivors of childhood cancer: a report from the International Late Effects of Childhood Cancer Guideline Harmonization Group. Lancet Oncol 16:e123–e136CrossRefPubMedPubMedCentral
Metadata
Title
Diabetology and oncology meet in a network model: union is strength
Authors
Marco Gallo
Luigi Gentile
Emanuela Arvat
Oscar Bertetto
Gennaro Clemente
Publication date
01-08-2016
Publisher
Springer Milan
Published in
Acta Diabetologica / Issue 4/2016
Print ISSN: 0940-5429
Electronic ISSN: 1432-5233
DOI
https://doi.org/10.1007/s00592-016-0839-z

Other articles of this Issue 4/2016

Acta Diabetologica 4/2016 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.